Imovax Polio (Poliovirus (Inactivated) Type 3 (Saukett Strain), Poliovirus (Inactivated) Type 2 (Mef-1 Strain), Po)

The vaccine contains chemically inactivated whole‑virus particles of poliovirus types 1, 2 and 3. After injection, the viral antigens are processed by antigen‑presenting cells, prompting the immune system to produce neutralizing antibodies and memory B cells. These antibodies block viral replication, providing active protection without causing disease.

The dosing regimen for Imovax Polio is determined by the prescribing healthcare professional based on age, vaccination history, and local immunization guidelines. The prescriber decides the number of doses, the interval between them, and the appropriate route (intramuscular or subcutaneous). No fixed dose can be stated without a medical prescription.

Safety data for Imovax Polio in pregnancy are limited, and the product is classified as pregnancy category unknown. It should be administered only when the expected benefit outweighs any potential risk to the fetus. Breastfeeding is not a contraindication, but mothers should discuss vaccination with their healthcare provider to assess any possible effects on the infant.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and the necessary import documentation.

Imovax Polio is an inactivated poliovirus vaccine (IPV) that contains all three serotypes, whereas oral poliovirus vaccine (OPV) uses live attenuated strains. IPV does not carry a risk of vaccine‑derived poliovirus and is preferred in settings with high immunization coverage, while OPV is easier to administer orally and induces intestinal immunity. Choice depends on national immunization policies and risk assessment.

The vaccine must be stored in a refrigerator at 2 °C to 8 °C. It should be kept in the original packaging to protect from light, must not be frozen, and should not be shaken vigorously. Prior to administration, allow the vial to reach room temperature for a short period if required by the manufacturer’s instructions.

Imovax Polio is given by a single‑dose injection into the deltoid muscle (intramuscular) or the subcutaneous tissue, as directed by the healthcare professional. The injection site is cleaned with an antiseptic, and the appropriate needle size is selected based on the patient’s age and body habitus. The vaccine is not intended for oral use.

The most serious adverse events reported are severe allergic reactions such as anaphylaxis, Guillain‑Barré syndrome, and, rarely, seizures following high fever. These events are uncommon but require immediate medical attention. Patients should be observed for a short period after vaccination to ensure prompt management if a serious reaction occurs.

Individuals with a documented severe allergy to any component of the vaccine, including the inactivated poliovirus strains, should not be vaccinated. Persons who have experienced a previous anaphylactic reaction to an IPV product should also avoid it. In all other cases, the vaccine can be administered after a risk‑benefit assessment by a qualified clinician.